Bank of Montreal Can Purchases Shares of 80,933 Liquidia Co. (NASDAQ:LQDA)

Bank of Montreal Can purchased a new stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 80,933 shares of the company's stock, valued at approximately $952,000. Bank of Montreal Can owned about 0.10% of Liquidia at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of LQDA. Barclays PLC grew its stake in shares of Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company's stock valued at $999,000 after buying an additional 72,591 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after purchasing an additional 210,753 shares during the last quarter. DMC Group LLC lifted its holdings in shares of Liquidia by 17.4% during the 4th quarter. DMC Group LLC now owns 16,302 shares of the company's stock valued at $192,000 after purchasing an additional 2,419 shares during the last quarter. Catalina Capital Group LLC raised its stake in Liquidia by 6.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company's stock worth $215,000 after acquiring an additional 1,125 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Liquidia by 3.5% during the 4th quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock worth $948,000 after purchasing an additional 2,741 shares during the period. Institutional investors own 64.54% of the company's stock.

Liquidia Stock Performance

Shares of LQDA stock traded up $0.18 during mid-day trading on Thursday, hitting $13.73. 91,351 shares of the stock traded hands, compared to its average volume of 961,179. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -8.45 and a beta of 0.23. The company's 50-day simple moving average is $14.49 and its 200-day simple moving average is $12.85. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank restated an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $26.63.

Insider Activity

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now owns 184,304 shares of the company's stock, valued at $2,501,005.28. The trade was a 1.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Kaseta sold 8,283 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $112,400.31. Following the completion of the sale, the chief financial officer now directly owns 396,315 shares in the company, valued at $5,377,994.55. This trade represents a 2.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,128 shares of company stock worth $450,072 in the last three months. 30.10% of the stock is owned by insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).